Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance

Hematology

Volumn 12, Issue 6, 2007, Pages 511-517

  Baran, Yusuf ^a,b   Gür, Bala ^a   Kaya, Pelin ^a   Ural, Ali Uǧur ^c   Avcu, Ferit ^c   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

AML; Cytosine arabinoside; Doxorubicin; MDR1; MRP1; Multidrug resistance

Indexed keywords

CD15 ANTIGEN; CD16 ANTIGEN; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; UPREGULATION;

ANTIGENS, CD15; CYCLOSPORINE; CYTARABINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RECEPTORS, IGG; UP-REGULATION;

EID: 35748937651     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701562535     Document Type: Article

References (37)

1. DeVita, VT, Hellman, S. and Rosenberg, SA (2005) Cancer: Principles & practice of oncology, Lippincott Williams & Wilkins, Philadelphia
2. Kolitz, JE, George, SL and Dodge, JE (2001) Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML)<60 years: Final induction results of CALGB 9621. Blood, 98, p. 461a.
3. Gottesman, MM, Fojo, T. and Bates, SE (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer, 2, pp. 48-58.
4. Krishna, R. and Mayer, LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11, pp. 265-283.
5. Litman, T., Druley, TE, Stein, WD and Bates, SE (2001) From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci, 58, pp. 931-959.
6. Karp, JE (2001) MDR modulation in acute myelogenous leukemia: Is it dead?. Leukemia, 15, pp. 666-667.
7. Ross, DD (2000) Novel mechanisms of drug resistance in leukemia. Leukemia, 14, pp. 467-473.
8. Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000) A family of drug transporters: The multidrug resistance-associated proteins. J Nat Cancer Inst, 92:16, pp. 1295-1302.
9. Doyle, LA and Ross, DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 22, pp. 7340-7358.
10. Leonard, GD, Polgar, O. and Bates, SE (2002) ABC transporters and inhibitors: New targets, new agents. Curr Opin Investig Drugs, 3, pp. 1652-1659.
11. Christina, L., Linn, H., Malin, B., Kourosh, L., Christer, P. and Staffan, E. (2004) Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells. Biochem Biophys Res Commun, 320, pp. 825-832.
12. Baker, EK and Osta, El A. (2003) The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res, 290, pp. 177-194.
13. Scotto, KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene, 22, pp. 7496-7511.
14. Dean, M., Hamon, Y. and Chimini, G. (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 42, pp. 1007-1017.
15. Ferry, DR, Traunecker, H. and Kerr, DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer, 32, pp. 1070-1081.
16. List, AF, Kopecky, KJ, Willman, CL, Head, DR, Persons, DL and Slovak, ML (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A southwest oncology group study. Blood, 98, pp. 3212-3220.
17. Twentyman, PR and Versantvoort, CH (1996) Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur J Cancer, 32, pp. 1002-1009.
18. Misbah, Q., Kieran, LO, Stacy, MF, Nicole, AW, William, RG and Hans, M. (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res, 11, pp. 2320-2326.
19. Hirrlinger, J., Konig, J., Keppler, D., Lindenau, J., Schulz, JB and Dringen, R. (2001) The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem, 76:2, pp. 627-636.
20. Baran, Y., Gündüz, U. and Ural, AU (2005) Expression of MDR1 gene in HL60 cells selected with vincristine. Turk J Cancer, 35:2, pp. 88-92.
21. Piskin, O., Ozcan, MA, Ozsan, GH, Ates, H., Demirkan, F. and Alacacioglu, I. (2007) Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines. Turk J Hematol, 24, pp. 23-27.
22. Hirose, M. (2002) Biology and modulation of multidrug resistance (MDR) in hematological malignancies. Int J Hematol, 76, pp. 206-211.
23. Filipits, M., Suchomel, RW, Dekan, G., Haider, K., Valdimarsson, G. and Depisch, D. (1996) MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res, 2:7, pp. 1231-1237.
24. Ogretmen, B., Schady, D., Usta, J., Wood, R., Kraveka, JM and Luberto, C. (2001) Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem, 276, pp. 24901-24910.
25. Chow, KU, Nowak, D., Kim, SZ, Schneider, B., Komor, M. and Boehrer, S. (2006) In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol Res, 53, pp. 49-61.
26. Gyorffy, B., Serra, V., Jurchott, K., Abdul-Ghani, R., Garber, M. and Stein, U. (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene, 24, pp. 7542-7551.
27. Baran, Y., Gündüz, Y. and Ural, AU (2006) Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol, 28:2, pp. 163-165.
28. Dong, BX, Chen, XQ, Wang, Z., Liang, R., Bai, QX and Huang, GS (2006) Difference of gene expression profiles between HL-60/VCR and HL-60 cells detected by human genome genechip. J Exp Hematol, 14:3, pp. 492-496.
29. Demidenko, ZN, Halicka, D., Kunicki, J., McCubrey, JA, Darzynkiewicz, Z. and Blagosklonny, MV (2005) Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res, 65:10, pp. 4401-4407.
30. Pu, QQ and Bezwoda, WR (1999) Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function. Mol Pharm, 56:1, pp. 147-153.
31. Higashigawa, M., Ido, M., Kuwabara, H., Hori, H., Ohkubo, T. and Kawasaki, H. (1991) Membrane transport of 1-β--arabinofuranosylcytosine and accumulation of 1-β--arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine. Leuk Res, 15:4, pp. 255-262.
32. Lopes, EC, Scolnik, M., Alvarez, E. and Hajos, SE (2001) Modulator activity of PSC 833 and cyclosporin-a in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells. Leuk Res, 25:1, pp. 85-93.
33. Hu, XF, Slater, A., Kantharidis, P., Rischin, D., Juneja, S. and Rossi, R. (1999) Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood, 93, pp. 4086-4095.
34. Weisburg, JH, Curcio, M., Caron, PC, Raghu, G., Mechetner, EB and Roepe, PD (1996) The multidrug resistance phenotype confers immunological resistance. J Exp Med, 183, pp. 2699-2704.
35. Morgan, RJ, Synold, TW, Gandara, D., Muggia, F., Scudder, S. and Reed, E. (2004) Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol, 54, pp. 283-289.
36. Kruijtzer, CM, Schellens, JH, Mezger, J., Scheulen, ME, Keilholz, U. and Beijnen, JH (2002) Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol, 20, pp. 4508-4516.
37. Elghetany, MT and Lacombe, F. (2004) Physiologic variations in granulocytic surface antigen expression: Impact of age, gender, pregnancy, race, and stress. J Leukoc Biol, 75, pp. 157-162.